Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22533795 | 1.00 | HDAC1 (0.44) | HDAC1HDAC6DCTPP1S1PR1ALOX5AP | |
| SCHEMBL29424701 | 0.82 | DCTPP1 (0.43) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533632 | 0.82 | DCTPP1 (0.43) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533977 | 0.81 | TP53 (0.45) | HDAC1HDAC6DCTPP1 | |
| SCHEMBL29424722 | 0.78 | HTR6 (0.43) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533430 | 0.78 | HTR6 (0.43) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533561 | 0.78 | HDAC1 (0.40) | HDAC1HDAC6DCTPP1ALOX5APGAA | |
| SCHEMBL29424814 | 0.75 | HTR6 (0.41) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533606 | 0.75 | HTR6 (0.41) | HDAC1HDAC6DCTPP1ALOX5APHTR6 | |
| SCHEMBL22533967 | 0.73 | DCTPP1 (0.46) | HDAC1HDAC6DCTPP1ALOX5APHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | claimed |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-11-17 | — | — | US | disclosed |
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | HDAC1 661/4885HDAC6 982/4885DCTPP1 7/4885 |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | HDAC1 697/4885HDAC6 1045/4885DCTPP1 7/4885 |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | HDAC1 697/4885HDAC6 1045/4885DCTPP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.